Indicators of lung function in children aged 6-14 years with mild persistent asthma during therapy with Montelukast (Singlon®)
The data on the dynamics of respiratory function indicators in children aged 6-14 years of life with mild persistent asthma, inappropriate criteria controlled, amid a three-month course of therapy with Singlon®. Shown that treatment with montelukast (Singlon®) in the form of chewable tablets 5 mg in children 6-14 years with mild persistent asthma, which has inappropriate criteria to controlled one, within three months to stabilize and to maintain respiratory function characterizing airway (FEV1, PEF, MEF25, 50, 75) at baseline. Patients aged 6-14 years with mild persistent asthma, with inappropriate criteria to the controlled by the end of 3 months of therapy with Singlon® recorded a significant increase in the indicator MVL.